SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of ... Read More